Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on ...

The study uncovers a unique reparative function of regulatory T cells (Tregs) in the process of fracture healing, a discovery that adds a new dimension to our understanding of the immune response in ...

Researchers have published the first description of the role of the ZFP36 family of RNA binding proteins in regulatory T cells (Tregs). Tregs are key to maintaining balance in the immune system and ...

Treg suppressive function, expressed as percentage of inhibition of proinflammatory T cell proliferation, showed a statistically significant increase over the course of the treatment period and was ...

Lim et al. demonstrate that Treg cells deficient in PD-1 occupy key spatial niches within the TME, with regulatory subsets organized near tumor cells dampening anti-tumor immunity (red and dark blue ...

COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...

The T cells in our blood fight against cancer, viruses and bacteria. Specific regulatory T cells are required to control faulty immune responses, and disruption in their function may lead to ...

Study met Primary and Secondary Endpoints for Safety and Regulatory T cell (Treg) Cell Population Enhancement, respectively, with no off-target effects on T effector lymphocytes, providing further ...